Compare VNCE & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | ATOS |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 36.2M |
| IPO Year | 2013 | 2010 |
| Metric | VNCE | ATOS |
|---|---|---|
| Price | $4.83 | $5.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.17 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 245.2K | 51.8K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.45 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $300,007,000.00 | $1,758.00 |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.48 | ★ N/A |
| Revenue Growth | ★ 2.23 | N/A |
| 52 Week Low | $1.19 | $0.53 |
| 52 Week High | $5.28 | $7.56 |
| Indicator | VNCE | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 74.74 | 53.42 |
| Support Level | $2.41 | $0.66 |
| Resistance Level | N/A | $5.56 |
| Average True Range (ATR) | 0.48 | 0.34 |
| MACD | 0.20 | -0.04 |
| Stochastic Oscillator | 85.34 | 50.97 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.